American Journal of Ophthalmology
Volume 139, Issue 6 , Pages 1101-1108 , June 2005

Evolving Management of Optic Neuritis and Multiple Sclerosis

  • Anthony C. Arnold, MD

      Affiliations

    • Corresponding Author InformationInquiries to Anthony C. Arnold, MD, Jules Stein Eye Institute, 100 Stein Plaza, UCLA, Los Angeles, CA 90095-7005; Fax (310) 267-1918

,Accepted 20 January 2005.

References 

  1. Beck RW , Cleary PA , Anderson MM , Keltner JL , Shults WT , Kaufman DI  Optic Neuritis Study Group . A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis . N Engl J Med . 1992;326:581–588
  2. Optic Neuritis Study Group . The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial . Neurology . 1997;49:1404–1413
  3. Beck RW , Cleary PA , Trobe JD , Kaufman DI , Kupersmith MJ , Paty DW  Optic Neuritis Study Group . The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis . N Engl J Med . 1993;329:1764–1769
  4. Beck RW , Cleary PA , Backlund JC  Optic Neuritis Study Group . The course of recovery after optic neuritis. The experience of the Optic Neuritis Treatment Trial . Ophthalmology . 1994;101:1771–1778
  5. The Optic Neuritis Study Group . Visual function 5 years after optic neuritis. Experience of the Optic Neuritis Treatment Trial . Arch Ophthalmol . 1997;115:1545–1552
  6. Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ , et al.   Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis . N Engl J Med . 2000;343:898–904
  7. CHAMPS Study Group . Interferon β-1a for optic neuritis patients at high risk for multiple sclerosis . Am J Ophthalmol . 2001;132:463–471
  8. Optic Neuritis Study Group . Visual function more than 10 years after optic neuritis (experience of the Optic Neuritis Treatment Trial) . Am J Ophthalmol . 2004;137:77–83
  9. Kapoor R , Miller DH , Jones SJ , et al.   Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis . Neurology . 1998;50:230–237
  10. Wakakura M , Mashimo K , Oono S , et al.   Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan . Japan J Ophthalmol . 1999;43:133–138
  11. Sellebjerg F , Nielsen HS , Frederiksen JL , Olesen J . A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis . Neurology . 1999;52:1479–1484
  12. Goodin DS . Perils and pitfalls in the interpretation of clinical trials (a reflection on the recent experience in multiple sclerosis) . Neuroepidemiology . 1999;18:53–63
  13. Goodin DS . Corticosteroids and optic neuritis [Letter to the Editor] . Neurology . 1993;43:632–633
  14. Beck RW . Corticosteroids and optic neuritis [Reply to Letter to the Editor] . Neurology . 1993;43:633–634
  15. Corbett JJ , Cruse JM . Corticosteroids and optic neuritis [Reply to Letter to the Editor] . Neurology . 1993;43:634
  16. Beck RW , Trobe JD  Optic Neuritis Study Group . The Optic Neuritis Treatment Trial. Putting the results in perspective . J Neuroophthalmol . 1995;15:131–135
  17. Kaufman DI , Trobe JD , Eggenberger ER , Whitaker JN . Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology . Neurology . 2000;54:2039–2044
  18. Miller DH , Newton MR , van der Poel JC , Halliday AM , Kendall BE , Johnson G , et al.   Magnetic resonance imaging of the optic nerve in optic neuritis . Neurology . 1988;38:175–179
  19. Dunker S , Wiegand W . Prognostic value of magnetic resonance imaging in monosymptomatic optic neuritis . Ophthalmology . 1996;103:1768–1773
  20. Kupersmith MJ , Alban T , Zeiffer B , Lefton D . Contrast-enhanced MRI in acute optic neuritis (relationship to visual performance) . Brain . 2002;125:812–822
  21. Cohen MM , Lessell S , Wolf PA . A prospective study of the risk of developing multiple sclerosis in uncomplicated optic neuritis . Neurology . 1979;29:208–213
  22. Rizzo JF , Lessell S . Risk of developing multiple sclerosis after uncomplicated optic neuritis (a long-term prospective study) . Neurology . 1988;38:185–190
  23. Beck RW , Arrington J , Murtagh FR , Cleary PA , Kaufman DI . Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Treatment Trial . Arch Neurol . 1993;50:841–846
  24. Optic Neuritis Study Group . High-and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis . Arch Ophthalmol . 2003;121:944–949
  25. Soderstrom M , Lindqvist M , Hillert J , Kall TB , Link H . Optic neuritis (findings on MRI, CSF examination, and HLA class II typing in 60 patients and results of a short-term follow-up) . J Neurol . 1994;241:391–397
  26. Ghezzi A , Martinelli V , Torri V , et al.   Long-term follow-up of isolated optic neuritis (the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests) . J Neurol . 1999;246:770–775
  27. Druschky A , Heckmann JG , Claus D , et al.   Progression of optic neuritis to multiple sclerosis (an 8-year follow-up study) . Clin Neurol Neurosurg . 1999;101:189–192
  28. Beck RW , Trobe JD  Optic Neuritis Study Group . What we have learned from the Optic Neuritis Treatment Trial . Ophthalmology . 1995;102:1504–1508
  29. Arnold AC , Pepose JS , Hepler RS , Foos RY . Retinal periphlebitis and retinitis in multiple sclerosis. Pathologic characteristics . Ophthalmology . 1984;91:255–262
  30. Lightman S , McDonald WI , Bird AC , et al.   Retinal venous sheathing in optic neuritis . Brain . 1987;110:405–414
  31. Rolak LA , Beck RW , Paty DW , Tourtellotte WW , Whitaker JN , Rudick RA . Cerebrospinal fluid in acute optic neuritis (experience of the Optic Neuritis Treatment Trial) . Neurology . 1996;46:368–372
  32. Compston DA , Batchelor JR , Earl CJ , McDonald WI . Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis . Brain . 1978;101:495–511
  33. Francis DA , Compston DA , Batchelor JR , McDonald WI . A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up . J Neurol Neurosurg Psychiatry . 1987;50:758–765
  34. Farris BK , Pickard DJ . Bilateral postinfectious optic neuritis and intravenous steroid therapy in children . Ophthalmology . 1990;97:339–345
  35. Brady KM , Brar AS , Lee AG , Coats DK , Paysse EA , Steinkuller PG . Optic neuritis in children (clinical features and visual outcome) . J AAPOS . 1999;3:98–103
  36. Parmley VC , Schiffman JS , Maitland CG , Miller NR , Dreyer RF , Hoyt WF . Does neuroretinitis rule out multiple sclerosis? . Arch Neurol . 1987;44:1045–1048
  37. Beck RW  Optic Neuritis Study Group . The Optic Neuritis Treatment Trial (three year follow-up results) . Arch Ophthalmol . 1995;113:136–137
  38. Trapp BD , Peterson J , Ransohoff RM , Rudick R , Mork S , Bo L . Axonal transaction in the lesions of multiple sclerosis . N Engl J Med . 1998;338:278–285
  39. Zivadinov R , Rudick RA , De Masi R , et al.   Effects of IV methylpredisolone on brain atrophy in relapsing-remitting MS . Neurology . 2000;57:1239–1247
  40. IFNB Multiple Sclerosis Study GroupUniversity of British Columbia MS/MRI Analysis Group . Interferon beta-1b in the treatment of multiple sclerosis (final outcome of the randomized controlled trial) . Neurology . 1995;45:1277–1285
  41. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group, University of British Columbia MS/MRI Analysis Group . PRISMS-4 (long-term efficacy of interferon β-1a in relapsing MS) . Neurology . 2001;56:1628–1636
  42. Li DKB , Paty DW  UBC MS/MRI Analysis Research Group PRISMS Study Group . Magnetic imaging results of the PRISMS trial (a randomized double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis) . Ann Neurol . 1999;46:197–206
  43. Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP  Copolymer 1 Multiple Sclerosis Study Group . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis (results of a phase III multicenter, double-blind placebo-controlled trial) . Neurology . 1995;45:1268–1276
  44. Galetta SL , Markowitz C , Lee AG . Immunomodulatory agents for the treatment of relapsing multiple sclerosis . Arch Intern Med . 2002;162:2161–2169
  45. Comi G , Filippi M , Wolinsky JS  European/Canadian Glatiramer Acetate Study Group . European/Canadian multicenter, double-blind, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis . Ann Neurol . 2001;49:290–297
  46. Optic Neuritis Study Group . Neurologic impairment 10 years after optic neuritis . Arch Neurol . 2004;61:1386–1389
  47. Ferguson B , Matyszak MK , Esiri MM , Perry VH . Axonal damage in acute multiple sclerosis lesions . Brain . 1997;120:393–399
  48. De Stefano N , Narayanan S , Francis GS , et al.   Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability . Arch Neurol . 2001;58:65–70
  49. Truyen L , van Waesberghe THTM , Barkof F , et al.   Accumulation of hypointense lesions (“black holes”) on T1 spin echo MRI correlates with disease progression in multiple sclerosis . Neurology . 1996;47:1469–1476
  50. Van Walderveen MA , Kamphorst W , Scheltens P , et al.   Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis . Neurology . 1998;50:1282–1288
  51. Yoles E , Wheeler LA , Schwartz M . Alpha-2 adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration . Invest Ophthalmol Vis Sci . 1999;40:65–73
  52. Miller DH , Khan OA , Shreemata WA , et al.   A controlled clinical trial of natalizumab for relapsing multiple sclerosis . N Engl J Med . 2003;348:15–23
  53. Vollmer T , Key L , Durkalski V , et al.   Oral simvastatin treatment in relapsing-remitting multiple sclerosis . Lancet . 2004;363:1607–1608

PII: S0002-9394(05)00100-5

doi: 10.1016/j.ajo.2005.01.031

American Journal of Ophthalmology
Volume 139, Issue 6 , Pages 1101-1108 , June 2005

Article Tools